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Abstract
Retinoid X receptor (RXR) has been implicated in several neoplastic diseases. Previously, we have shown that RXR-α
is downregulated in human and rodent colonic tumors, suggesting a potential target for colon cancer prevention
(http://www.cancer.org/Cancer/ColonandRectumCancer/DetailedGuide/colorectal-cancer-key-statistics). Experi-
ments were designed to assess the chemopreventive efficacy of the selective RXR agonist bexarotene for the sup-
pression of intestinal tumorigenesis in ApcMin/+ mice. Before the efficacy studies, we determined that the maximal
tolerated dose in C57BL/6Jmice was less than 400 ppm. For the efficacy study, 6-week-old male and female C57BL/
6J-ApcMin/+ mice (nine mice per group) were fed diets containing 0, 30, and 60 ppm of bexarotene or 200 ppm
of bexarotene for 80 days before intestinal tumors were evaluated. Dietary administration of 30 and 60 ppm of
bexarotene suppressed the intestinal polyp formation by 38% (P< .015) and 60% (P< .0001) in males, respectively,
and by 8.5% and 37% (P < .007) in females, respectively. Also, significant inhibition (50%-100%) of colonic tumor
formation was observed in both male and female mice with bexarotene treatment. Administration of 200 ppm of
bexarotene showed significant suppression of tumor formation (66%, P < .0001); however, it had significant tox-
icity. Intestinal tumors of bexarotene-fed mice showed significantly reduced expression of proliferating cell nuclear
antigen (60%, P < .0001), cyclin D1, and cyclooxygenase 2 and increased RXR-α messenger RNA and uptake of
oleate (34%, P < .01). Also, bexarotene-fed mice showed dose-dependent suppression of serum triglycerides
(25%-72%, P < .0001) and inflammatory cytokines.
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Introduction
Despite improved advances in early diagnosis and treatment, colon
cancer remains the leading cancer problem in the United States
and worldwide in both men and women. In recent years, the annual
incidence rate of colon cancer in the United States has fallen slowly,
but colon cancer remains the second most common cause of cancer-
related deaths in the United States [1]. A significant increase is
observed in the incidence of colorectal cancers in the developing
world. Several agents have been and currently are being investigated
for chemoprevention of colon cancer, including cyclooxygenase 2
(COX-2) inhibitors, tyrosine kinase inhibitors, and retinoids, to cite
a few [2–6]. Although retinoids are promising chemopreventive agents
in animals and humans, they are not generally used for cancer preven-
tion because of their toxicity [7]. Naturally occurring and synthetic reti-
noids activate different retinoid receptors. All-trans retinoic acid (RA)
binds only retinoic acid receptors (RARs), whereas 9-cis RA is an agonist
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for both RARs and retinoid X receptors (RXRs). The synthetic rexinoid
bexarotene is a highly selective RXR agonist with low affinity for RARs
[8]. It is evident that RXR plays vital roles in multiple signaling pathways,
including in carcinogenesis through nuclear receptor family members.
The loss of RXR function will likely negatively impact physiological roles
of the nuclear receptors.
In adenomatous polyposis coli (APC) mutant mice, the nuclear
accumulation of β-catenin leads to altered signaling, causing polyp
formation. The degradation of cytoplasmic β-catenin was specifically
induced by RXR-α but not by RAR-α [9]. RXR-α has unique char-
acteristics that distinguish it from the other RAR and RXR subtypes
[10,11]. It is the most abundant of the RXR subtypes, it mediates the
heterodimerization of RARs with other members in the thyroid hor-
mone nuclear transcription receptor family, it is essential for the func-
tional activation of RARs by their ligands, and it has the ability to
form homodimers with itself or heterodimers with other nuclear re-
ceptors such as peroxisome proliferator–activated receptor γ and
vitamin D. In addition, RXR-α has been suggested to be a key player
in the carcinogenesis of several types of cancer, including prostate,
ovarian, skin, and leukemia [12–14].
Modulation of multiple cancer pathways by a single agent is an
attractive approach for targeted therapy. Although significant progress
has been made toward understanding RAR/RXR–mediated signaling
pathways, the molecular mechanisms underlying the gene modula-
tions caused by ligand-activated RXRs are highly complex and in-
completely understood. Our previous studies with a natural RXR-α
agonist, β-ionone, have shown inhibition of the proliferation of
malignant colon cells and suppression of aberrant crypt formation in
an azoxymethane (AOM)-induced rat colon carcinogenesis model
[2]. To develop agents that will prevent cancer with increased efficacy
by activating multiple pathways, we investigated the cancer preven-
tive activity of the RXR-selective rexinoid, bexarotene (LGD1069;
Targretin). In this study, we investigated the ability of bexarotene to
prevent the development of small intestinal (SI) and colon tumors in
ApcMin/+ mice. The results demonstrated that bexarotene significantly
prevented the development of SI and colon tumors by modulating
markers of tumor growth.
Materials and Methods
Chemicals
Bexarotene was kindly provided by the National Cancer Institute’s
chemopreventive drug repository (Rockville, MD). Primary anti-
bodies anti–RXR-α (1:500) and anti–proliferating cell nuclear antigen
(PCNA) were from Santa Cruz Biotechnology (Santa Cruz, CA);
monoclonal and polyclonal horseradish peroxidase–conjugated second-
ary antibodies (1:1000) were from Santa Cruz Biotechnology. Multi-
Analyte ELISArray kit was from SA Biosciences (Frederick, MD).
Breeding and Genotyping of ApcMin/+ Mice
All animal experiments were performed in accordance with the in-
stitutional guidelines of the American Council on Animal Care and
were approved by the Institutional Animal Care and Use Committee
at the University of Oklahoma Health Sciences Center (OUHSC).
Male ApcMin/+ (C57BL/6J) and female wild-type littermate mice were
initially purchased from The Jackson Laboratory (Bar Harbor, ME) as
founders, and our own breeding colony was established in the OUHSC
rodent barrier facility and genotyped according to the vendor’s instruc-
tions. All mice were housed three per cage in ventilated cages under
standardized conditions (21°C, 60% relative humidity, 12-hour light/
12-hour dark cycle, 20 air changes per hour). All mice were allowed
ad libitum access to the respective diets and automated tap water purified
by reverse osmosis.
Diets
All ingredients for the semipurified diets were purchased from Bioserv
(Frenchtown, NJ) and stored at 4°C before diet preparation. Diets were
based on the modified American Institute of Nutrition (AIN)-76A diet.
Bexarotene was premixed with a small quantity of diet and then blended
into bulk diet using a Hobart mixer. Both control and experimental
diets were prepared weekly and stored in a cold room. Agent content
in the experimental diets was determined periodically in multiple sam-
ples taken from the top, middle, and bottom portions of individual diet
preparations to verify uniform distribution. In this study, experimental diets
were prepared with AIN-76A diet containing 0, 30, 60, or 200 ppm
of bexarotene.
Determination of Bexarotene Maximum Tolerable Dose
in C57BL/6J Mice
At 6 weeks of age, groups of male C57BL/6J mice (6/group) were fed
the modified AIN-76A diet containing the various levels of bexarotene
(50, 100, 200, 400, and 800 ppm; Figure 1A). Body weights were re-
corded twice weekly for 6 weeks. All animals were examined daily for
any symptoms of toxicity. At the end of 8 weeks, all animals were killed,
and colon, small intestine, stomach, liver, and kidney were examined
grossly under a dissection microscope for any abnormalities. The max-
imum tolerable dose (MTD) is defined as the highest dose that causes
no more than a 10% weight decrement compared with the appropriate
control diet group and does not produce mortality or any external signs
of toxicity that would be predicted to shorten the natural life span of the
animal. These external signs of toxicity include roughened coat, ill-kept
appearance, chromodacryorrhea, rhinitis, and prostration, to cite a few.
Bioassay: Intestinal Tumorigenesis in ApcMin/+ Mice
The antitumor efficacy of bexarotene was assessed in male and
female ApcMin/+ mice according to the experimental protocol summa-
rized in Figure 1A. Five-week-old mice were randomized for age and
average body weights in each group (nine ApcMin/+ mice in each
group), and mice were fed the AIN-76A diet for 1 week. At 6 weeks
of age, mice were fed control or experimental diets containing 0, 30,
60, or 200 ppm of bexarotene until termination of the study. Body
weight, animal behavior, and food and fluid consumption were mon-
itored weekly for signs of weight loss, lethargy, or decreased consump-
tion that might indicate intestinal obstruction or anemia. Mice were
checked routinely for any other abnormalities. After 12 weeks, all
mice were killed by CO2 asphyxiation, blood was collected by heart
puncture, and serum was separated by centrifugation and stored at
−80°C until further analysis. This point in time was chosen to min-
imize the risk of intercurrent mortality caused by severe progressive
anemia, rectal prolapse, or intestinal obstruction, which usually occurs
among Min mice at older than 20 weeks of age. After necropsy, the
entire intestinal tract was harvested, flushed with 0.9% NaCl, and
opened longitudinally from the esophagus to the distal rectum. The
tissue was flattened on filter paper to expose the tumors and briefly
frozen on dry ice to aid visual scoring of tumors. The number, loca-
tion, and size of visible tumors in the entire intestine were determined
under a dissection microscope (×5). All tumors were scored and sub-
divided by location (duodenal, jejunal, and ileum and colon) and size
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(>2, 1-2, or <1 mm in diameter). This procedure was completed by
two individuals who were blinded to the experimental group and the
genetic status of the mice. Colonic and other SI tumors that required
further histopathologic evaluation were fixed in 10% neutral-buffered
formalin, embedded in paraffin blocks, and processed by routine
hematoxylin and eosin staining. In addition, multiple samples of
tumors from the small intestines were harvested and stored in liquid
nitrogen for analysis of COX-2 expression levels.
Assessment of Serum Triglycerides and Packed Cell Volume
Triglycerides were quantified in the nonhemolyzed serum using
Infinity Triglycerides Liquid Stable Reagent (Thermo Scientific,
Middletown, VA) as per the manufacturer’s instructions. For packed
cell volume (PCV)/hematocrit measurement, blood was sampled by
cardiac puncture with a 21-gauge needle attached to a 1-ml heparinized
syringe and dispensed into a plastic microfuge tube on ice. Microhema-
tocrit tubes containing ammonium heparin were then placed in the mi-
crofuge tube and centrifuged in a hematocrit centrifuge for 5 minutes.
Lipid Extraction, Methylation, and Gas Chromatography
Lipid extraction was performed by the addition of chloroform-
methanol (2:1) to partition the lipid and nonlipid constituents from
biopsy samples. This method was previously described by Bligh and
Dyer [15]. Lipid esters were then methylated by adding anhydrous
methanol in the presence of potassium hydroxide after drying down
the lipid extract. Methyl esters were finally solubilized in hexane.
Two microliters of the esterified lipid sample was separated by gas
chromatography (GC2010; Shimadzu, Columbia, MD), and the relative
abundance (expressed as percentages) of individual lipid constituents was
determined within each sample. Standards containing known amounts
of pure fatty acids were run under the same conditions and retention
times of the lipid samples were matched with those of the standards.
Histopathologic Analyses
After the intestines were scored, a segment of the small intestine
(beginning at the jejunum) and colon was fixed in 10% formalin
for 24 hours and then Swiss rolled and paraffin embedded for path-
ologic analysis.
Immunohistochemistry
To evaluate the effect of bexarotene, we assessed the PCNA expres-
sion in intestinal tumor tissue sections along with RXR-α expression
by immunohistochemistry, as described. Briefly, paraffin sections
were deparaffinized in xylene, rehydrated through graded ethanol
Figure 1. (A) Experimental design for the evaluation of the chemopreventive efficacy of bexarotene administered in the diet from 6 weeks
of age to the end of the experiment. AIN-76A was the control diet. The study was terminated after 80 days. For details about animals and
treatments, see Materials and Methods. (B) C57BL/6J male mice were exposed to five different doses of bexarotene for 8 weeks to
observe the MTD in mice. Changes in body weight in this period for control mice and mice on bexarotene diet are plotted in the graph.
Bexarotene at 400 ppm caused significant body weight loss and that at 800 ppm was toxic, with 50% survival by the end of the study.
(C) Changes in body weight over time in male ApcMin/+ treated with or without 200 ppm of bexarotene. Statistically significant differ-
ences in bodyweight between bexarotene-treated and control groups were observed. Bexarotene-treated animals were found to lose
weight, and 50% survival was observed by the end of the study. (D) Changes in body weight over time for male ApcMin/+ mice treated
with or without 30 or 60 ppm of bexarotene. Statistically significant differences in bodyweight between bexarotene-treated and control
groups were observed. Bexarotene-treated animals were found to gain weight by the end of the study. (E) Changes in body weight over
time for female ApcMin/+ mice treated with 0, 30, or 60 ppm of bexarotene. Differences in bodyweight gain by high-dose bexarotene-
treated group versus control groups were observed.
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solutions to distilled water, and washed in phosphate-buffered saline
(PBS). Antigen retrieval was carried out by heating sections in 0.01 M
citrate buffer (pH 6) for 30 minutes in a boiling water bath. Endog-
enous peroxidase activity was quenched by incubating in 3%H2O2 in
PBS for 5 minutes. Nonspecific binding sites were blocked using
protein block for 20 minutes. Sections were then incubated overnight
at 4°C with 1:500 dilutions of rabbit monoclonal antibody against
PCNA and RXR-α (Santa Cruz Biotechnology). After several washes
with PBS, the slides were incubated with secondary antibody for
PCNA and RXR-α for 2 hours. The color reaction was developed
with 3,3′diaminobenzidine, according to the manufacturer’s instruc-
tions given in the kit supplied by Zymed Laboratories (Camarillo, CA).
Substituted nonimmune rabbit immunoglobulins for primary antibodies
were used as negative controls. Scoring using light microscopy at ×400
magnification was performed by two investigators blinded to the identity
of the samples. Cells with brown nuclei were considered positive. The
proliferation index was determined by dividing the number of positive
cells per polyp (upper, middle, and lower) and multiplying by 100.
RXR-α, COX-2, and Cyclin D1 Messenger RNA Expression
by Reverse Transcription–Polymerase Chain Reaction
Total RNA from tumor samples was extracted using ToTALLY
RNA Kit for isolation of total cellular RNA (Ambion, Foster City,
CA) as per the manufacturer’s instructions. Equal quantities of DNA-
free RNA were used for reverse transcription reactions for making com-
plementary DNA using SuperScript reverse transcriptase (Invitrogen,
Grand Island, NY). Polymerase chain reaction (PCR) was performed
for RXR-α, COX-2, and cyclin D1 using the following conditions:
COX-2 denaturation at 94°C for 2 minutes, followed by 35 cycles
at 94°C for 30 seconds, 52°C for 30 seconds, and 72°C for 1 minute.
Oligonucleotide primer sequences used were as follows: 5′-CCTGT-
GCCTGATGATTGC-3′ (sense) and 5′-CGGTGAAACTCTGGC-
TAG-3′ (antisense). RXR-α denaturation was carried out at 94°C for
5 minutes, followed by 35 cycles at 94°C for 45 seconds, 60°C for
20 seconds, and 72°C for 1 minute. Oligonucleotide primer sequences
used were as follows: 5′-CTTTGACAGGGTGCTAACAGAGC-3′
(sense) and 5′-ACGCTTCTAGTGACGCATACACC-3′ (antisense).
Cyclin D1 denaturation was done at 94°C for 3 minutes, followed by
35 cycles at 94°C for 30 seconds, 60°C for 20 seconds, and 72°C for
45 seconds. The oligonucleotide primer sequences used for the cyclin
D1 gene were as follows: 5′-ATGGAACACCAGCTCCTGTG-3′
(sense) and 5′-ACCTCCAGCATCCAGGTGGC-3′ (antisense).
PCR was done using the Taq polymerase Master Mix (Qiagen,
Valencia, CA). The PCR products were visualized and photographed
under UV illumination.
Inflammatory Cytokines Assay
Determination of inflammatory cytokine levels in serum was evalu-
ated by enzyme-linked immunosorbent assay (ELISA; SA Biosciences)
as per the manufacturer’s instruction. The mouse Inflammatory Cyto-
kines and Chemokines Multi-Analyte ELISArray Kit analyzes a panel
of 12 proinflammatory cytokines in serum all at once using an ELISA
protocol under uniform conditions. The cytokines and chemokines
included in this array are interleukin (IL) 1A, IL-1β, IL-2, IL-4,
IL-6, IL-10, IL-12, IL-17A, interferon γ (IFN-γ), tumor necrosis
factor α (TNF-α), granulocyte–colony-stimulating factor (G-CSF),
and granulocyte-macrophage colony-stimulating factor (GM-CSF).
Results are expressed as nanograms per milliliter of serum. Determina-
tion was carried out in triplicates from each sample.
Sample Size and Statistical Analyses
A least-squares regression statistical analysis (power α = 0.8; tradi-
tional 0.05 level test) was applied, using approximately 0.7 to 1.8
(mean) as an estimate for colon tumor multiplicity in ApcMin/+ mice
based on previous studies [16] and estimating a approximately 25%
to 75% decrease in SI polyps with bexarotene based on studies in other
tumor types in other models [17]. For the tumor assay, a minimum of
eight mice per group was determined to be adequate to identify a dif-
ference between control and treated mice of more than 25%. For the
cellular and molecular outcome parameters, a sample size of three to six
(depending on marker variability) per treatment was calculated to be
adequate to produce effects that are statistically distinguishable. All results
are expressed as means ± SE. Differences in body weights were analyzed
by analysis of variance, and differences in tumor multiplicity and volume
were determined by Student’s t test. Differences were considered sig-
nificant at the P < .05 level. All statistical analysis was performed in
GraphPad Prism Software 5.0 (GraphPad Software, Inc, SanDiego, CA).
Results
MTD and Overt Toxicity of Bexarotene
Wild-type mice fed 400 and 800 ppm of bexarotene showed a
retardation of body weight gain. Notably, mice fed 800 ppm of
bexarotene had only 50% survival (Figure 1B), and the remaining
mice showed more than 25% body weight loss. Although mice fed
400 ppm of bexarotene showed body weight loss, this dose had no
effect on the survival rates. In addition, both 400- and 800-ppm diets
caused significant liver toxicity. Mice fed 200 ppm or less bexarotene
showed no change in body weight or any observable toxicity by histo-
pathologic analysis. This MTD bioassay suggests that the bexarotene
MTD is more than 200 ppm or less than 400 ppm. Based on these
studies, we selected 200 ppm of bexarotene as the highest dose for
efficacy studies.
Efficacy and Toxicity of 200 ppm of Bexarotene
in Male ApcMin/+ Mice
ApcMin/+ mice fed 200 ppm of bexarotene were observed to lose
weight similarly to ApcMin/+ mice fed the control diet (Figure 1C ).
In contrast to wild-type mice (MTD assay), male ApcMin/+ mice fed
200 ppm of bexarotene showed significant toxicity and had approxi-
mately 50% survival by the end of the 12 weeks of bexarotene expo-
sure. Despite the toxicity, the chemopreventive efficacy of 200 ppm of
bexarotene was significant, with 67% inhibition of total SI polyps
(55.7 tumors in control vs 18.6 tumors in treated mice, P < .0001;
Figure 2A). Based on this information, we selected nontoxic doses
of bexarotene (30 and 60 ppm) for further efficacy studies in both
male and female ApcMin/+ mice.
Efficacy of 30 and 60 ppm of Bexarotene in Male
and Female ApcMin/+ Mice
ApcMin/+ mice fed 30 or 60 ppm of bexarotene showed somewhat
higher body weights with no noticeable signs of toxicity compared to
control ApcMin/+ mice. Also, mice fed 30 or 60 ppm of bexarotene
diets showed less anemia than those fed a control diet. Statistically
significant (P < .05) differences in body weights were observed be-
tween the dietary groups (Figure 1, D and E ). As expected, control
diet-fed ApcMin/+ mice began to lose body weight at approximately
12 weeks of age because of intestinal obstruction and progressive anemia.
To assess the effects of bexarotene on intestinal tumor formation in
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APC mutant transgenic mice, we examined the polyp number and size
in different regions of the small intestine and colon. Dietary adminis-
tration of 30 and 60 ppm of bexarotene significantly suppressed total SI
polyps in a dose-dependent manner in ApcMin/+ male and female mice,
by 38.2% to 59.9% (P < .015 to P < .0001) or 8.5% to 36.9%, respec-
tively (P < .007; Figure 2, B and E). The numbers of large (>2 mm) and
small polyps were more significantly decreased with the high-dose
treatment in male mice (Figure 2D). Male mice fed 30 or 60 ppm of
bexarotene had 44% or more than 60% fewer polyps, respectively, with
a diameter greater than 2 mm and 54% or 68% fewer polyps with a
diameter of approximately 1 mm, respectively. Untreated female mice
had fewer small polyps of approximately 1 mm than untreated male
mice (∼8 vs 23 per mouse) but had similar numbers of intermediate
or large polyps. In female, mice fed 60 ppm of bexarotene had ap-
proximately 35% suppression of polyps greater than 2 mm compared
with control mice and 26% fewer polyps of approximately 1 mm
(Figure 2G). In the female mice, 30 ppm of bexarotene caused a de-
crease in numbers of the larger polyps accompanied by an increase in
numbers of the small approximately 1-mm polyps. This may be due to
inhibition of proliferation that halted the small polyps to increase in
size by bexarotene treatment. Male mice treated with bexarotene (30
or 60 ppm) had a 50% reduction in the number of colonic tumors
(control 1.22 vs treated 0.55 tumors per mouse, P < .05; Figure 2C).
Female mice treated with 30 and 60 ppm of bexarotene showed
approximately 50% and 100% reduction, respectively, in the colonic
tumors (Figure 2F ).
Figure 2. (A) Inhibition of total SI polyp formation in ApcMin/+ male mice by 200 ppm of bexarotene. Data are means ± SE of nine animals
per treatment group. The control and treated groups are significantly different from one another (P< .0001). (B) Inhibition of total SI polyp
formation in ApcMin/+ male mice by bexarotene (30 and 60 ppm). Data are means ± SE of nine animals per treatment group. Control and
treated groups are significantly different from one another (P < .015 or P < .0001). (C) Average number of colon tumors per mouse in
control and treated ApcMin/+male mice. A significant (P< .05) inhibition of colon tumors was observed with both low-dose and high-dose
bexarotene. Data are means ± SE of nine animals per treatment group. (D) Tumor sizes in the small intestine of ApcMin/+ male mice.
Intestines were divided into sections and examined under a stereomicroscope; the size of the polyps was determined. Data are given as
means ± SE of nine animals per treatment condition. Tumors greater than 2mm in size and those 1mm in size were suppressed/inhibited
approximately 75% in high-dose bexarotene-treated mice. (E) Inhibition of total SI polyp formation in ApcMin/+ female mice by bexarotene
(30 and 60 ppm). Data are means ± SE of nine animals per treatment condition. Control and treated groups are significantly different from
one another (P< .007). (F) Average number of colon tumors per mouse in control and treated ApcMin/+ femalemice. A significant (P< .04)
inhibition of colon tumors was observed with low-dose bexarotene and 100% inhibition was observed with a high dose. Data are means ±
SE of nine animals per treatment condition. (G) Tumor sizes in the small intestine of ApcMin/+ male mice. Intestines were divided into
sections and examined under a stereomicroscope; the size of the polyps was determined. Data are given as means ± SE of nine animals
per treatment condition. The numbers of tumors greater than 2 mm and those approximately 1 mm in diameter were decreased ∼75% in
high-dose bexarotene-treated mice.
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RXR-Mediated Increase in Oleate in Colonic Mucosa and
Down-regulation of COX-2 Messenger RNA Expression
in Response to Bexarotene
Because RXRs forms heterodimers with liver X receptor (LXR)
receptors, which are known to regulate the levels of fatty acids in
enterocytes, we performed an experiment to determine whether
bexarotene treatment had any effect on fatty acids in colonic mucosa.
Subtoxic doses of bexarotene caused in an increase in metabolically
active oleate, an n-9 monounsaturated fatty acid, in colonic mucosa
from male and female C57BL/6J mice. In females, both 30 and
60 ppm of bexarotene caused a significant (P < .08 and P < .01, re-
spectively) increase in oleate with not much difference in other fatty
acids (Figure 3B). In males, some increase in oleate was observed at
60 ppm, but it did not reach statistical significance (Figure 3A). The
increase in oleate was associated with a concomitant reduction in
COX-2 messenger RNA (mRNA) concentrations (Figure 3, C and D).
These results correlate well with the inhibition of colon tumors in
female ApcMin/+ mice.
Modulation of RXR-α in Intestinal Tumors
Expression levels of RXR-α, which are important in various signal-
ing pathways of antiproliferation and apoptosis, were analyzed in SI
polyps by reverse transcription–PCR and immunohistochemistry
(Figures 3 and 4). A dose-dependent increase in RXR-α mRNA
expression was observed in bexarotene-treated intestinal polyps
(Figure 3, C and D). Dietary administration of 60 ppm of bexarotene
resulted in a significant increase in RXR-α protein expression in intes-
tinal polyps compared with control polyps as observed with immuno-
staining (Figure 4A). These results correlate with the down-regulation
of COX-2 and uptake of oleate with bexarotene treatment (Figure 3).
Effect of Dietary Administration of Bexarotene on SI Polyp
Proliferative Index (PCNA) and Cyclin D1 mRNA
Expression Levels
Figure 4 (A and B) demonstrates the effects of bexarotene on tumor
cell proliferation as measured by PCNA overexpression. Qualitative
microscopic examination of PCNA-stained sections showed a substantial
decrease in PCNA-positive cells in the SI polyps from bexarotene-fed
mice compared with the untreated controls. Bexarotene at 60 ppm sig-
nificantly suppressed proliferation in the SI polyps compared with con-
trol polyps (Figure 4B). The quantification of PCNA staining (not
shown in the figure) revealed 55.1 ± 5.4 (mean ± SEM) PCNA-positive
cells in control polyps compared with 20.2 ± 4.4 (mean ± SEM) PCNA-
positive cells in bexarotene-treated SI polyps, accounting for a decrease
in the proliferation index by approximately 60%. The quantification of
PCNA staining showed 60.6 ± 3.3 (mean ± SEM) PCNA-positive cells
in control tumors compared with 30 ± 2.4 (mean ± SEM) PCNA-
positive cells in colon tumors from bexarotene-treated mice, accounting
for a decrease in the proliferative index by approximately 50%. Similarly,
the expression of cyclin D1 mRNA levels showed a strong decrease in
intestinal polyps of bexarotene-treated mice compared with untreated
ApcMin/+ mice (Figure 3, C and D). The reduced expression of PCNA
and cyclin D1 suggests a decreased tumor cell proliferation in treated mice.
Figure 3. (A) Effects of bexarotene on oleate uptake in intestinal mucosa of male mice. A modest uptake of oleate was observed in
colonic mucosa from male mice treated with 60 but not 30 ppm of bexarotene compared with that in the untreated animals. (B) Effects
of bexarotene on oleate uptake in intestinal mucosa of female mice. A significant uptake of oleate (P < .008 to P < .01) was observed
in the colonic mucosa from female mice mouse treated with 30 or 60 ppm of bexarotene compared with that in untreated animals.
(C) Modulatory effects of bexarotene on RXR-α, COX-2, and cyclin D1 mRNA expression in SI polyps of treated and untreated ApcMin/+
male mice. A significant dose-dependent increased expression of RXR-αmRNA was observed on bexarotene treatment (30 and 60 ppm).
A significant dose-dependent suppression of COX-2 and cyclin D1 mRNA was observed on bexarotene treatment in ApcMin/+ mice. (D)
Modulatory effects of bexarotene on RXR-α, COX-2, and cyclin D1 mRNA expression in colon tumors of treated and untreated ApcMin/+
female mice. A significant dose-dependent increase in expression of RXR-αmRNA was observed on bexarotene treatment. A significant
dose-dependent suppression of COX-2 and cyclin D1 mRNA was observed on bexarotene treatment (30 ppm) in ApcMin/+ mice.
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Bexarotene Decreases Serum Triglycerides and Increases PCV
Untreated ApcMin/+ mice had a significant increase in serum tri-
glyceride (TG) compared with control wild-type C57BL/6J mice.
Both male and female ApcMin/+ mice fed bexarotene diets showed a
dose-dependent suppression in serum TGs (25.2%, P < .01 or
32.9%, P < .001 for male and female, respectively, with 30 ppm;
and 72%, P < .0001 or 90%, P < .0001 with 60 ppm; and 87%
P < .0001 for male ApcMin/+ mice with 200 ppm of bexarotene;
Figure 5, A and B). TG levels of ApcMin/+mice fed high dose bexarotene
were comparable to those of untreated wild-type mice (Figure 5, A
and B). Also, we observed a dose-dependent increase in PCV in blood
from bexarotene-fed male and female ApcMin/+ mice compared with
control ApcMin/+ mice (Figure 5, C and D).
Modulation of Inflammatory Cytokines
Expression levels of inflammatory or COX-2–inducing cytokines
(IL-1β, IL-2, IL-6, IL-10, IL-12, IFN-γ, TNF-α, G-CSF, GM-CSF)
are significantly (P < .05 to P < .0001) decreased in serum from
bexarotene-treated (60 ppm) animals (Figure 6). GM-CSF was reduced
by approximately 95%, and IL-2 and IL-12 were completely inhibited.
No significant difference was observed in the expression levels of anti-
inflammatory cytokine IL-1A or in IL-17A (Figure 6).
Discussion
In this study, we demonstrated that a selective RXR agonist bexaro-
tene inhibited intestinal tumorigenesis in ApcMin/+ mice, a model for
human familial adenomatous polyposis. Bexarotene treatment caused
a decrease in serum TGs and enhanced uptake of oleate, and caused
tumor growth inhibition, suggesting that the RXR pathway is an
important target for colon cancer prevention. The suppressive effect
of bexarotene on the development of colonic tumors also was closely
correlated with a decrease in proinflammatory cytokines. Although
the value of the ApcMin/+ mouse as model for predicting efficacy of
chemopreventive agents in humans is a subject of debate, results
obtained in this model [18,19] did forecast the efficacy of COX
inhibitors, such as sulindac and celecoxib, to retard adenoma recur-
rence in humans [20,21].
The expression of proliferation marker PCNA is significantly re-
duced in the treated polyp, with no effect on normal crypt (Figure 4).
This could be due to tumor-specific suppression of proliferation by
bexarotene, and it is well known that tumor cells that proliferate
much faster contain very high levels of PCNA compared with normal
crypt cells. Additional experiments would be needed to determine
whether and to what extent bexarotene influences the normal crypt
cell PCNA levels. The chemopreventive effect of bexarotene in the
ApcMin/+ mouse was, to a certain extent, dose related. Bexarotene at
200 ppm, which reduced SI polyp number by approximately 75%,
could not extend mouse survival because of significant toxicity; after
12 weeks of feeding, only 50% of the mice survived. However, lower
subtoxic doses of bexarotene (30 and 60 ppm) significantly inhibited
SI tumorigenesis by 38.2% and 59.9% (P < .015 to P < .0001) or
8.5% and 36.9% (P < .007), for male and female mice, respectively.
It is intriguing that bexarotene showed better efficacy against SI
tumors in males compared to female mice and, in contrast, better
efficacy against colon tumors in female than in male mice. The rea-
sons for these differences need further investigation. However, it is
possible that hormonal differences or differences in bioavailability
of bexarotene in male versus female mice might have played a role.
The differences between male and female mice in the dose-response
relationship suggest that the bexarotene dose must be optimized sep-
arately for males and females for optimal colon cancer chemoprevention.
The recommended dosage of bexarotene is 300 mg/m2 per day clini-
cally (cancer patients). Data reported by others suggest that dosages of
retinoids up to 10 and 50 mg/kg per day used in mice (female MMTV-
erbB2 transgenic mice) can achieve peak plasma levels that are similar to
those from human trials using 200 to 400 mg/m2 per day [22–24],
Figure 4. (A) Increase in RXR-α protein expression in the nucleus of bexarotene-treated intestinal tumors. Serial paraffin sections of
intestinal tumors from ApcMin/+ were subjected to immunohistochemical analysis using an anti–RXR-α polyclonal antibody. Marked
accumulation of RXR-α is clear in the nucleus of tumors in treated animals compared with that in tumors from control animals. Top
panel is representative of SI polyps; bottom panel is representative of colon tumors. (B) Serial paraffin sections of small intestine and
colon from ApcMin/+ mice were subjected to immunohistochemical analysis using an anti-PCNA monoclonal antibody. Intense positive
staining for PCNA in the tumor region of control animals was observed. Staining for PCNA was decreased in the nuclei of tumors from
bexarotene-treated animals. Top panel represents SI polyps; bottom panel represents colon tumors. Original magnifications, ×20.
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which is equivalent to approximately 6 to 10 mg/kg body weight per
day. Thus, 60 ppm (∼10 mg/kg body weight per day) of bexarotene
used in the present study should be very close to the clinical dosage (by
kilogram body weight); however, it is much lower than the dosage used
by others in previous studies in mice.
The regulation of growth and differentiation by rexinoids results from
direct and indirect effects on gene expression mediated by the RAR and
RXR nuclear receptors. RXRs form heterodimers with LXR receptors
and regulate the levels of fatty acids [25]. Hence, in the presence of
bexarotene, the increased expression of RXR and its interaction with
LXR might have caused the increase in oleate in colonic mucosa. Kim
et al. [26] showed that the expression of several rexinoid-regulated bio-
markers is modulated in vivo in mammary glands frommice treated with
bexarotene. Microarray analysis showed up-regulation of stearoyl-CoA
desaturase (regulatory enzyme involved in the synthesis of the monoun-
saturated fatty acids palmitoleate and oleate) and down-regulation of
COX-2. Bexarotene binding to RXR may induce the absorption of
oleate, which affects the expression of COX-2, an important gene in
colon tumor development. COX-2 is induced by a variety of mitogenic
and inflammatory stimuli. It is well known that COX-2 expression is
markedly elevated in colorectal cancer in both humans and rodents,
and COX-2 plays an important role in cancer cell proliferation [27].
The COX-2 molecule could be a second messenger for transcrip-
tional action of the fatty acid oleate as reported by Duplus et al. [28].
In the current study, COX-2 levels in colon polyps from ApcMin/+
mice were much greater than those in wild-type mice. Treatment
with bexarotene increased oleate levels in colon mucosa, and this
increase somewhat correlated with reduced colon tumors. Oleate is
reported to lower cholesterol levels, thereby reducing atherosclerosis
and the risk of cardiovascular disease. It reduces insulin resistance,
thereby improving glucose maintenance, improves immune function,
and provides protection against certain types of cancer [29]. Our
findings also suggest that RXR may regulate COX-2 and, thus, the
production of prostaglandins, which are known to play a key role in
colon tumor development.
Epidemiologically, a positive association between hypertriglyceridemia
and colorectal cancer development has been reported [30]. Also, an ex-
perimental rodent study showed a positive effect of serum TG on the
development of aberrant crypt foci [31]. Niho et al. [32–34] and our
laboratory [16] recently showed that a hyperlipidemic state is associated
with intestinal polyp formation in Apc-deficient mice, and this was
attributed mainly to down-regulation of lipoprotein lipase in Apc
mutant mice. They observed that peroxisome proliferator–activated
receptor ligands and lipoprotein lipase activator reduce serum TG levels
Figure 5. (A) Dose-dependent decrease in TGs in male ApcMin/+ mice treated with bexarotene. The TG level in bexarotene-treated
ApcMin/+ mice was significantly lower than that in the untreated animals (P = .005 to P < .0001). In the 200-ppm bexarotene-treated
group, the TG levels were reduced to approximately 80% of levels observed in wild-type mice. (B) Dose-dependent decrease in TGs in
female ApcMin/+ mice treated with bexarotene. The decrease to 40% to 85% of control was significant at P < .05 to P < .0001. (C)
PCVs of ApcMin/+ male control versus treated animals. A significant increase in PCV was observed in male mice treated with high-
dose (60 ppm) bexarotene. (D) PCVs of ApcMin/+ female control versus treated animals. A significant increase in PCV was observed in
female mice treated with 60 ppm of bexarotene.
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and suppress intestinal polyp formation in Apc-deficient mice [32–34].
Other laboratory investigations also have shown that RXR-selective
agonists increase the transcription of apolipoprotein C-III, possibly
interfering with plasma lipid clearing [35]. Lipid metabolism and the
intracellular transport of bioactive molecules are critical in the modula-
tion of proliferation through interactions with nuclear receptors. Our
finding that administration of bexarotene improved hyperlipidemia and
suppressed intestinal polyp formation in the ApcMin/+ mice is consistent
with these other findings. ApcMin/+ mice showed approximately six-fold
higher serum TG levels compared to wild-type control mice, but both
male and female ApcMin/+mice fed bexarotene showed a dose-dependent
suppression of serum TG levels. Importantly, decreased serum TG
levels were highly correlated with decreased intestinal polyp number
and tumor size induced by bexarotene.
The ability of bexarotene to interfere with tumorigenesis also
could be due to the inhibition of inflammatory cytokines. We ob-
served inhibition of IL-2, IL-12, IFN-γ, and other proinflammatory
cytokines. Recent studies show that retinoids inhibit the production
of several inflammatory cytokines by activated macrophages through
functional interactions between their receptors (RXR and RAR) and
nuclear factor-κB, a crucial transcription factor for IL-12 gene
expression [36]. Furthermore, IL-1β has been shown to enhance
the production of vascular endothelial growth factor through IL-2,
which was shown to induce angiogenesis in colon cancer cells [37].
TNF-α and IL-1β are key cytokines involved in inflammation, immu-
nity, and cellular organization [38]. In this study, the expression of
TNFα and IL-1β proteins was substantially upregulated in the serum
of control ApcMin/+ mice. Bexarotene treatment reduced the expres-
sion of TNFα and IL-1β protein in the serum of ApcMin/+ mice. Be-
cause the induction of COX-2 is regulated by TNFα and IL-1β, these
cytokine effects may play important roles in tumor promotion. Thus,
the suppression of TNFα and IL-1β expression by bexarotene may
contribute to the low frequency of large tumors (size ∼1.5-2 mm)
as observed in this study.
In conclusion, the dietary administration of bexarotene could effec-
tively suppress intestinal tumor development in the ApcMin/+ mice by
affecting multiple factors, including up-regulation of RXR-α, and by
decreasing COX-2, inflammatory cytokines, and hyperlipidemia, all
of which are involved in colon carcinogenesis. Collectively, these data
suggest a role of bexarotene in chemoprevention of intestinal cancers.
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